Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism

Erem C., KOÇAK M., NUHOĞLU İ., YILMAZ M., ÜÇÜNCÜ Ö.

EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol.160, no.5, pp.863-868, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 160 Issue: 5
  • Publication Date: 2009
  • Doi Number: 10.1530/eje-09-0069
  • Journal Name: EUROPEAN JOURNAL OF ENDOCRINOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.863-868
  • Karadeniz Technical University Affiliated: Yes

Abstract

Background and objectives: Primary hyperparathyroidism (PHPT) is associated with increased cardiovascular mortality kind morbidity. Little is known about hemostatic features of patients with PHPT. To Our knowledge, plasma tissue factor pathway inhibitor (TFPI) and thrombin-activatable fibrinolysis inhibitor (TAFI) levels in these patints have not been investigated. Therefore, the main purpose of this study was to evaluate the markers of endogenous coagulation/fibrinolysis, including TFPI and TAFI, and to investigate the relationships between serum calcium and PTH and these hemostatic parameters in patients with PHPT.